Meanwhile, circulating triglycerides are a risk factor for the survival of patients with ER‐negative breast cancer, but they have no significant impact on the survival of patients with the other molecular subtypes of breast cancer distinguished by ER and HER2. This evidence concerns the gene ERBB2 and breast carcinoma.